ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,993.25
0.32%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Syros Pharmaceuticals Inc (SYRS)

  7. Syros Pharmaceuticals Inc (SYRS) News

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SYRS
DateTimeSourceHeadlineSymbolCompany
07/05/202414:00Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202412:00Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
09/04/202412:00Business WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
02/04/202421:30Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202411:30Business WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202410:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
25/03/202411:00Business WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
20/03/202411:00Business WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/02/202412:00Business WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
15/02/202401:56Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202401:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202400:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
13/02/202423:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202412:00Business WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
02/01/202421:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
26/12/202322:19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202321:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202321:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202312:27Business WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
14/12/202321:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
12/12/202321:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
08/12/202321:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
06/12/202321:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
06/12/202312:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
06/12/202312:00Business WireSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineNASDAQ:SYRSSyros Pharmaceuticals Inc
05/12/202322:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
21/11/202312:30Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202312:30Business WireSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202311:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SYRS

Your Recent History

LSE
BARC
Barclays
LSE
PET
Petrel Resources
LSE
WG.
Wood Group (john)
LSE
GOLD
LSE
GFM
Griffin Mining
LSE
MIRI
Mirriad Advertising
LSE
GKP
Gulf Keystone Petroleum
LSE
JSE
Jadestone Energy
LSE
SAR
Sareum
LSE
THUS
Thus
LSE
NEXN
Nexxen
LSE
IHR
Impact Healthcare Reit
LSE
TERN
Tern
LSE
CNR
Condor Gold
LSE
LTI
Lindsell Train Investment
LSE
RKH
Rockhopper Exploration
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved